GAI
SPRY icon

General American Investors’s ARS Pharmaceuticals SPRY Stock Holding History

General American Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.08M Buy
1,133,046
+405,892
+56% +$3.49M 0.54% 49
2026
Q1 		$5.84M Buy
727,154
+167,195
+30% +$1.6M 0.38% 56
2025
Q4 		$6.52M Buy
+559,959
New +$5.45M 0.37% 58

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

General American Investors's SPRY Position: Q2 2026 in Review

General American Investors increased its ARS Pharmaceuticals (SPRY) stake by 56% in Q2 2026, buying an estimated $3.49M and bringing the position to 1,133,046 shares worth $9.08M. The position accounts for 0.54% of the portfolio, ranked #49.

General American Investors first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • General American Investors held 1,133,046 shares of ARS Pharmaceuticals worth $9.08M as of Q2 2026.
  • General American Investors bought 405,892 ARS Pharmaceuticals shares in Q2 2026, an estimated $3.49M.
  • ARS Pharmaceuticals made up 0.54% of General American Investors's portfolio in Q2 2026, its #49 holding.
  • General American Investors first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on General American Investors's 13F filing for Q2 2026, filed 31 Jul 2026.